UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
May 10, 2017 12:03 pm UTC| Business
RA’ANANA, Israel and NEW YORK, May 10, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with...
UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
May 10, 2017 12:03 pm UTC| Business
RA’ANANA, Israel and NEW YORK, May 10, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with...
UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
May 10, 2017 12:03 pm UTC| Business
RA’ANANA, Israel and NEW YORK, May 10, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with...
May 10, 2017 12:03 pm UTC| Business
PLYMOUTH MEETING, Pa., May 10, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the...
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 10, 2017 12:03 pm UTC| Business
Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8...
KEMET Reports Preliminary Fourth Quarter and Fiscal Year 2017 Results
May 10, 2017 12:03 pm UTC| Business
Net sales for the quarter up 5.0% to $197.5 million compared to the prior quarter ended December31, 2016Gross margin for fiscal year 2017 of 24.6% compared to 22.2% for the prior fiscal year 2016Cash Balance at March31,...
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 10, 2017 12:03 pm UTC| Business
Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8...